Needham Reiterates Buy on Biogen, Maintains $294 Price Target

BenzingaJun 28 17:33

Wedbush Adjusts Price Target on Vigil Neuroscience to $23 From $22 on Heels of Sanofi Investment, Maintains Outperform Rating

MT NewswiresJun 28 17:18

Amgen Analyst Ratings

BenzingaJun 28 01:48

Argus Research Maintains Buy on Amgen, Raises Price Target to $340

BenzingaJun 28 01:48

RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target

BenzingaJun 27 21:58

Pfizer Analyst Ratings

BenzingaJun 27 00:10

Eli Lilly and Co Analyst Ratings

BenzingaJun 27 00:10

Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target

BenzingaJun 27 00:10

Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target

BenzingaJun 27 00:09

Biogen Analyst Ratings

BenzingaJun 26 23:08

RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target

BenzingaJun 26 23:08

Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117

MT NewswiresJun 26 18:45

Johnson & Johnson Analyst Ratings

BenzingaJun 25 22:54

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

BenzingaJun 25 22:53

Jefferies Financial raised the target price of Eli Lilly and Co. to $1015.

Gelonghui FinanceJun 25 17:18

Eli Lilly and Co Analyst Ratings

BenzingaJun 24 22:47

Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target

BenzingaJun 24 22:46

Jefferies Adjusts Price Target on Eli Lilly to $1,015 From $994

MT NewswiresJun 24 18:15

Gilead Sciences Analyst Ratings

BenzingaJun 21 01:40

Baird Maintains Neutral on Gilead Sciences, Maintains $80 Price Target

BenzingaJun 21 01:39